Splenic Angiosarcoma and Numerous Liver Metastases Presenting the Kasabach-Merritt Phenomenon
Toshiro Masuda1, Toru Beppu2, Yasunori Nagayama3
1Department of Surgery, Yamaga City Medical Center, Kumamoto, Japan.
Anticancer Research
|March 28, 2025
Summary
Metastatic splenic angiosarcoma with Kasabach-Merritt phenomenon requires accurate diagnosis and treatment. Chemotherapy, like paclitaxel and pazopanib, can control this rare cancer and its associated coagulopathy.
Area of Science:
- Oncology
- Vascular Tumors
- Hematology
Background:
- Splenic angiosarcoma is a rare and aggressive malignancy.
- Metastatic splenic angiosarcoma can present with Kasabach-Merritt phenomenon, a serious coagulopathy.
Purpose of the Study:
- To investigate the diagnostic approach and treatment strategy for metastatic splenic angiosarcoma.
- To evaluate the management of Kasabach-Merritt phenomenon in this context.
Main Methods:
- Case report of a 76-year-old male with splenic angiosarcoma and Kasabach-Merritt phenomenon.
- Diagnostic imaging included contrast-enhanced CT and MRI.
- Treatment involved anticoagulant-fibrinolytic therapy, surgical intervention for ischemia, and chemotherapy (paclitaxel, pazopanib).
Main Results:
- Diagnosis confirmed via immunohistochemical analysis of liver tumors.
- Patient experienced jejunal ischemia requiring surgical resection and ileostomy.
- Chemotherapy with paclitaxel and pazopanib led to stable disease and controlled Kasabach-Merritt phenomenon.
Conclusions:
- Accurate diagnosis, surgical intervention, and chemotherapy are crucial for managing metastatic splenic angiosarcoma with Kasabach-Merritt phenomenon.
- Kasabach-Merritt phenomenon serves as an indicator of chemotherapy response.
- Further research into novel chemotherapies is warranted.
Keywords:
Kasabach-Merritt phenomenonSplenic angiosarcomadisseminated intravascular coagulopathyliver metastasesMore Related Videos
Related Concept Videos
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:25Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
01:22Portal Hypertension
Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...